The efficacy and safety of different dosage of amoxicillin-voronazan dual therapy for 14 days in Helicobacter pylori eradication: A prospective, randomized, open clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200064874

Enrollment

Unknown

Registered

2022-10-20

Start date

2021-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Group 1:amoxicillin (1g bid) and voronazan (20mg bid) for 14 days

Group 2:amoxicillin (1g tid) and voronazan (20mg bid) for 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. Patients receiving initial treatment; 3. Positive Hp infection was confirmed by endoscopic pathology or 13C urea breath test.

Exclusion criteria

Exclusion criteria: 1. Allergy to amoxicillin; 2. Zollinger-Ellison syndrome or GC or upper gastrointestinal bleeding or active peptic ulcer; 3. The coexistence of significant concomitant illnesses including heart diseases, renal failure, hepatic disease, previous abdominal surgery, or lactation or pregnancy; 4. Use of proton pump inhibitors and antibiotics used within one month; 5. Not willing to attend this study.

Design outcomes

Primary

Measure	Time frame
eradication;	—

Secondary

Measure	Time frame
adverse event rate;	—

Countries

China

Contacts

Public ContactLyu Nonghua

The First Affiliated Hospital of Nanchang University

lunonghua@ncu.edu.cn+86 13707086809

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026